dc.date.accessioned | 2021-08-19T15:38:41Z | |
dc.date.available | 2021-08-19T15:38:41Z | |
dc.date.created | 2021-04-06T14:27:52Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Juzeniene, Asta Stenberg, Vilde Yuli Bruland, Øyvind Larsen, Roy Hartvig . Preclinical and clinical status of psma-targeted alpha therapy for metastatic castration-resistant prostate cancer. Cancers. 2021, 13:779(4), 1-25 | |
dc.identifier.uri | http://hdl.handle.net/10852/86842 | |
dc.description.abstract | Bone, lymph node, and visceral metastases are frequent in castrate-resistant prostate cancer patients. Since such patients have only a few months’ survival benefit from standard therapies, there is an urgent need for new personalized therapies. The prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer and is a molecular target for imaging diagnostics and targeted radionuclide therapy (theragnostics). PSMA-targeted α therapies (PSMA-TAT) may deliver potent and local radiation more selectively to cancer cells than PSMA-targeted β− therapies. In this review, we summarize both the recent preclinical and clinical advances made in the development of PSMA-TAT, as well as the availability of therapeutic α-emitting radionuclides, the development of small molecules and antibodies targeting PSMA. Lastly, we discuss the potentials, limitations, and future perspectives of PSMA-TAT. | |
dc.language | EN | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Preclinical and clinical status of psma-targeted alpha therapy for metastatic castration-resistant prostate cancer | |
dc.type | Journal article | |
dc.creator.author | Juzeniene, Asta | |
dc.creator.author | Stenberg, Vilde Yuli | |
dc.creator.author | Bruland, Øyvind | |
dc.creator.author | Larsen, Roy Hartvig | |
cristin.unitcode | 185,50,0,0 | |
cristin.unitname | Det medisinske fakultet | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 1902437 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Cancers&rft.volume=13:779&rft.spage=1&rft.date=2021 | |
dc.identifier.jtitle | Cancers | |
dc.identifier.volume | 13 | |
dc.identifier.issue | 4 | |
dc.identifier.doi | https://doi.org/10.3390/cancers13040779 | |
dc.identifier.urn | URN:NBN:no-89477 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 2072-6694 | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/86842/2/Preclinical%2Band%2BClinical%2BStatus%2Bof%2BPSMA-Targeted%2BAlphaTherapy%2Bfor%2BMetastatic%2BCastration-Resistant%2BProstate%2BCancer.pdf | |
dc.type.version | PublishedVersion | |
cristin.articleid | 779 | |